Archive: March 2022

Managing Adverse Events of Immunotherapy in Breast Cancer

H&O  Which immunotherapy agents have been approved for use in breast cancer?  HS  The first immunotherapy agent to receive accelerated approval for breast cancer in the […]

Autologous and Allogeneic CAR T-Cell Therapies: Spotlighting the “Brain-to-Vein” Time

H&O How has the introduction of chimeric antigen receptor (CAR) T-cell therapy impacted the management of patients with lymphoma?  ML  CAR T-cell therapy has revolutionized the […]

Highlights From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

January 17-19, 2022 • San Francisco, California, and Online  Addition of Olaparib to Abiraterone Improves Progression-Free Survival in First-Line Metastatic Castration-Resistant Prostate Cancer The addition of […]

Letter From the Editor: Read My Lips

It will be close to springtime when this editorial is published, although I am writing it on a cold and rainy afternoon in February. It is […]

New Strategies for the Treatment of Immune Thrombocytopenia

H&O  Which guidelines should physicians refer to when taking care of patients with immune thrombocytopenia (ITP)?  CK  The American Society of Hematology (ASH) published updated guidelines […]

Talking to the FDA About Dose Optimization and the Aims of Project Optimus

H&O  What is Project Optimus, and what prompted the creation of this project? MT  Project Optimus is a new initiative from the Oncology Center of Excellence […]

Management of Acute Lymphoblastic Leukemia in Older Adults

Abstract: Acute lymphoblastic leukemia, commonly known to affect the younger population, is a disease that is affecting the elderly in an increasing amount as the human […]

The Treatment Landscape for Gastroesophageal Adenocarcinomas

Abstract: The treatment landscape for gastroesophageal adenocarcinomas has significantly changed over the last year. The addition of nivolumab to first-line chemotherapy has led to survival benefit […]

Emerging Data for Venetoclax in Chronic Lymphocytic Leukemia

H&O What study data led the US Food and Drug Administration (FDA) to approve venetoclax for chronic lymphocytic leukemia (CLL)? SO In CLL, venetoclax (Venclexta, AbbVie/Genentech) […]

Back to Archive